A New Approach to Publishing High-Quality Scientific Content in the JMD  by Sobel, Mark E.
The Journal of Molecular Diagnostics, Vol. 13, No. 1, January 2011
Copyright © 2011 American Society for Investigative Pathology
and the Association for Molecular Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.jmoldx.2010.11.015Editorial
A New Approach to Publishing High-Quality
Scientific Content in the JMDMolecular diagnostics is no longer a fledgling discipline,
but it remains a quickly-evolving one, constantly adapting
to new technologies and the changing needs of the sci-
ence that it serves. Likewise, The Journal of Molecular
Diagnostics, now in its thirteenth year of publication, has
become an established and respected venue for the
molecular diagnostics community while sharing the same
characteristics of responsiveness and adaptation.
Strong Foundations in the Past
With this issue, the JMD carries a new designation: Pub-
lished by Elsevier, Inc. This is the next in a succession of
evolutionary advances for the Journal. In November 1999,
the Association of Molecular Pathology (AMP), in partner-
ship with the American Society for Investigative Pathology
(ASIP), published Volume 1 of The Journal of Molecular Di-
agnostics as Part B of The American Journal of Pathology
(AJP) under the editorial leadership of Nelson Fausto, edi-
tor-in-chief, and Karen Kaul, senior editor. The Journal came
out from the AJP umbrella in 2001, and in 2002 Karen Kaul
assumed the mantle of Editor-in-Chief. The history of the
Journal was recently reflected on in the editorials of the
November 2008 issue, celebrating its first 10 years.1,2,3
Since its inception, the Journal has been self-published by
AMP and ASIP, maintaining a Journal Editorial Office in their
shared Society executive office suite in Bethesda.
I have had the opportunity to serve both AMP and ASIP
in the capacities of Council member, President, and now
Executive Officer, and I have witnessed and been proud
to be an active force in the Journal’s evolution and
growth, starting with the early discussions within the AMP
Council to develop an official journal and the decision of
the ASIP leadership to expand the editorial office of AJP
to publish a high-quality research journal to meet the
needs of the molecular diagnostics community in part-
nership with AMP. Since 1999, both the Journal and its
Society owners have adapted to a dynamic scientific
landscape, encompassing major scientific discoveries in
genome science as well as new technologies.
In 2010, Timothy O’Leary succeeded Karen Kaul as
Editor-in-Chief, and this year begins another landmark year
of change for the Journal. Scientific publishing is undergo-
ing tremendous evolutionary pressures from factors such as
the Open Access movement, adoption of new publishingand discoverability technologies, and increased globaliza-
tion of content. This changing climate has put traditional
revenue streams such as institutional subscriptions at risk,
while also demanding higher levels of diligence, invest-
ment, and innovation. With that in mind, as well as an eye
toward increasing the reach and impact of the JMD, the
Societies have entered into a relationship with Elsevier to
manage its publication. The Societies still own the Journal,
maintain copyright, and retain full editorial control, but pro-
duction, promotion, and other publishing support services
are now provided by a contract publisher.
Future Evolution
We are confident that our managed publishing arrange-
ment with Elsevier will provide technological advancement
and financial stability, with the potential to greatly expand
the readership and global visibility of The Journal of Molec-
ular Diagnostics. The commitment of AMP and ASIP to the
Journal has not changed. We consider this the next stage in
our advocacy for the science of molecular pathology and in
meeting the needs of our constituents – the readers, au-
thors, and Society members who comprise our scientific
community. Our authors will not notice any changes in the
manuscript and submission process, which remain under
the editorial leadership of our Editor-in-Chief Timothy
O’Leary and themanagement of our Journal Editorial Office.
We will continue to support full compliance with enhanced
public access requirements of the National Institutes of
Health, Wellcome Trust, and other funding body require-
ments by depositing published articles on behalf of their
funded authors for public release in PubMed Central (PMC)
and UKPMC. Articles on the Journal website will continue to
become publicly available one year after publication.
The Journal website will sport a new look on the
Elsevier platform as well as being more widely available
through other content platforms such as ScienceDirect
and JournalsConsult. Features such as journal CME will
remain, and non-CME registrants will be able to preview
CME test questions. In the coming months, we hope to
add additional features to the online platform, as well as
introduce stylistic changes to the print Journal. One thing
that will remain constant will be the high-quality science
and production value that have been the hallmarks of The
Journal of Molecular Diagnostics.
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JMD January 2011, Vol. 13, No. 1The Journal has thrived by adapting to the rapid changes
in the field of molecular diagnostic pathology, and its ability
to respond to changes in the publishing landscape is no
different. We are excited about the new possibilities that the
relationship with Elsevier brings. This partnership places the
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